<DOC>
	<DOCNO>NCT00993668</DOCNO>
	<brief_summary>The purpose trial ass affect Certolizumab Pegol ( CZP ) treatment antibody response T cell-independent T cell-dependent immunization use pneumococcal influenza vaccine , respectively .</brief_summary>
	<brief_title>Assessing Use Certolizumab Pegol Adult Subjects With Rheumatoid Arthritis Antibody Response When Receiving Influenza Virus Pneumococcal Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects must least 18 year old screening visit Subjects must able understand information provide give write informed consent , able willing comply study requirement Female subject must either postmenopausal least 1 year , surgically incapable childbearing , effectively practice acceptable method contraception ( either oral/parenteral/implantable hormonal contraceptive , intrauterine device barrier spermicide . Abstinence acceptable method . Subjects must agree use adequate contraception study 10 week last dose CZP . Male subject must agree ensure female partner ( ) use adequate contraception study 10 week subject receives last dose CZP Subjects must diagnosis adultonset Rheumatoid Arthritis ( RA ) least 6months duration define 1987 American College Rheumatology ( ACR ) classification criterion Subjects must active RA disease define : ≥ 4 tender joint ( 28 joint count ) Screening Week 0 ; ≥ 4 swollen joint ( 28 joint count ) Screening Week 0 Subjects diagnosis inflammatory arthritis ( eg. , psoriatic arthritis ankylose spondylitis ) Subjects history infect joint prosthesis time prosthesis still situ Subjects must free define prohibited medication biological therapy Subjects receive experimental nonbiological therapy , within outside clinical trial 3 month prior Week 0 Subjects receive experimental biological agent past 3 month within 5 halflives prior Week 0 ( whichever longer ) Subjects receive previous treatment biological response modifier therapy RA result severe hypersensitivity reaction anaphylactic reaction . Subjects history pneumococcal influenza infection last 3 month Subjects history pneumococcal vaccination last 5 year Subjects history influenza vaccination within last 6 month Female subject breastfeed , pregnant , plan become pregnant trial within 3 month follow last dose study drug Subjects history chronic recurrent infection ( 3 episode require antibiotics/antivirals precede year ) , recent serious lifethreatening infection within 6 month ( include herpes zoster ) , current sign symptom may indicate infection Subjects splenectomy Subjects hypersensitivity reaction previous pneumococcal influenza vaccination Subjects know hypersensitivity egg egg product component vaccine Subjects history GuillainBarre syndrome Subjects history tuberculosis , active tuberculosis , positive chest xray tuberculosis , positive purify protein derivative ( PPD ) skin test ( define induration ≥5 mm ) . Subjects candidate PPD test due prior severe reaction PPD test history PPD positivity must undergo Elispot test instead tuberculosis evaluation . Subjects test positive via PPD indeterminate positive Elispot test , latent tuberculosis rule , may enrol study provide treat ( eg. , isoniazid 9 month ) treatment initiate least 4 week prior first administration CZP Subjects high risk infection ( eg. , presence leg ulcer indwell urinary catheter , persistent recurrent chest infection , bedridden wheelchair bound subject ) Subjects history lymphoproliferative disorder include lymphoma sign symptom suggestive lymphoproliferative disease Subjects know concurrent acute chronic viral hepatitis B C positive hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCVAb ) Subjects know human immunodeficiency virus ( HIV ) infection Subjects receive live attenuate vaccination within 12 week prior Week 0 Concurrent malignancy history malignancy ( carcinoma cervix basal cell carcinoma successfully treat 5 year prior screen ) Subjects Class III Class IV congestive heart failure accord New York Heart Association ( NYHA ) 1964 classification criterion Subjects history , suspect , demyelinate disease central nervous system ( eg. , multiple sclerosis optic neuritis ) Subjects current recent history severe , progressive , and/or uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological cerebral disease Subjects condition ( eg. , clinically significant laboratory value ) Investigator 's judgement would make subject unsuitable inclusion study Subjects history adverse reaction polyethylene glycol ( PEG )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>influenza</keyword>
	<keyword>vaccine</keyword>
	<keyword>pneumococcal vaccine</keyword>
	<keyword>certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>